ORIC files new $200M ATM offering; prior program fully utilized

Oric Pharmaceuticals, Inc.

New prospectus supplement filed Feb 26, 2026 for up to $200M in shares via Jefferies.
Prior $200M program (2024) terminated after raising $139.7M gross from 13.48M shares.
No further sales will be made under the 2024 prospectus supplement.
Legal opinion from Wilson Sonsini filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.